The CD300LD Knockout SK-OV-3 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout population derived from the SK-OV-3 human ovarian adenocarcinoma cell line. This polyclonal format preserves heterogeneous gene-disruption profiles, providing a robust loss-of-function model without clonal selection. Targeting of CD300LD disrupts the activating immune receptor, enabling functional investigation in tumor cell signaling and immune interaction studies.
SK-OV-3 is a well-characterized model of high-grade serous ovarian carcinoma, originally established from ascites of a 64-year-old female patient. The line harbors a TP53-null background, an activating PIK3CA H1047R mutation, an ARID1A mutation, and HER2 amplification, making it especially valuable for studying oncogenic signaling, tumorigenesis, metastasis, and drug resistance mechanisms in ovarian cancer research.
CD300LD is an activating immune receptor that signals via the DAP12 adaptor. Engagement by ligands such as lipoteichoic acid, bacterial pathogens, or phosphatidylserine, as well as stimulation by IFN-?? or TNF-??, promotes recruitment of SYK kinase. Downstream, this activates the PI3K?CAKT and NF-??B pathways, driving secretion of TNF-?? and IL-6 and regulating phagocytosis-related processes. In SK-OV-3 cells, the constitutive PI3K?CAKT activation from the PIK3CA H1047R mutant intersects with CD300LD-dependent signaling, potentially modulating cytokine output and cellular responses.
Within ovarian adenocarcinoma, CD300LD may influence immune evasion and tumor-promoting inflammation. The PIK3CA mutation in SK-OV-3 cells creates a hyperactive PI3K?CAKT?CmTOR loop that could synergize with CD300LD signaling. Knockout of CD300LD in this genetic context enables dissection of its role in proliferation, immune checkpoint modulation, and tumor-immune crosstalk, making it a relevant model for exploring pathways that connect oncogenic and immune signaling.
This polyclonal knockout model supports a wide range of applications: Western blotting for phospho-AKT and NF-??B, RT-qPCR and ELISA for TNF-?? and IL-6, flow cytometric assessment of surface markers, phagocytosis assays, and drug sensitivity profiling. Co-culture systems with macrophages or other immune cells facilitate studies on tumor cell clearance and immune evasion. It also serves as a screening platform for inhibitors targeting CD300LD-dependent pathways. For additional information or ordering, contact Ascent Research.
